

Tina-quant Complement C3c ver.2**Order information**

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
03001938 322	Tina-quant Complement C3c ver.2 (100 tests)	System-ID 07 6560 0 Roche/Hitachi cobas c 311, cobas c 501/502
Materials required (but not provided):		
11355279 216	Calibrator f.a.s. Proteins (5 x 1 mL)	Code 656
11355279 160	Calibrator f.a.s. Proteins (5 x 1 mL, for USA)	Code 656
10557897 122	Precinorm Protein (3 x 1 mL)	Code 302
10557897 160	Precinorm Protein (3 x 1 mL, for USA)	Code 302
11333127 122	Precipath Protein (3 x 1 mL)	Code 303
11333127 160	Precipath Protein (3 x 1 mL, for USA)	Code 303
05117003 190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 391
05947626 190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 391
05947626 160	PreciControl ClinChem Multi 1 (4 x 5 mL, for USA)	Code 391
05117216 190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 392
05947774 190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 392
05947774 160	PreciControl ClinChem Multi 2 (4 x 5 mL, for USA)	Code 392
04489357 190	Diluent NaCl 9 % (50 mL)	System-ID 07 6869 3

English**System information**

For **cobas c** 311/501 analyzers:

C3C-2: ACN 036

For **cobas c** 502 analyzer:

C3C-2: ACN 8036

Intended use

In vitro test for the quantitative determination of Complement C3c in human serum and plasma on Roche/Hitachi **cobas c** systems.

Summary^{1,2,3,4}

Activation of the complement system takes place via a classical and an alternative route. The two pathways come together in a joint terminal path. As complement factor C3 is a factor common to both pathways, the concentration of C3 and its degradation products (including C3c) can be evaluated as a parameter for activation of the complement system.

Lowered values are indicative of activation. Additional differentiation can be made by determining C4. If the C4 level is normal, then activation of the alternative route is likely. Depressed values are observed in a number of inflammatory and infectious diseases. Primary causes are systemic lupus erythematosus (SLE), rheumatoid arthritis, subacute bacterial endocarditis, viremia, parasitic infections or bacterial sepsis. A considerable decrease in C3 can be found in patients with partial lipodystrophy or membranoproliferative glomerulonephritis when the C3-nephritis factor is present.

As an acute phase protein, C3 is produced to an increased extent during inflammatory processes. It is elevated in systemic infections, non-infectious chronic inflammatory conditions (primarily chronic polyarthritis) and physiological states (pregnancy). The elevation rarely exceeds twice the normal value and can mask a reduction in the current consumption.

A variety of methods, such as nephelometry, radial immunodiffusion and turbidimetry, are available for the determination of complement factor C3.

Test principle²

Immunoturbidimetric assay.

Human C3c forms a precipitate with a specific antiserum which is determined turbidimetrically.

Reagents - working solutions

R1 TRIS buffer: 100 mmol/L, pH 8.0; polyethylene glycol: 3.0 %; preservative

R2 Anti-human C3c antibody (goat): dependent on titer; TRIS buffer: 33 mmol/L; preservative

R1 is in position B and R2 is in position C.

Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

Reagent handling

Ready for use

Storage and stability**C3C-2**

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 6 weeks

Diluent NaCl 9 %

Shelf life at 2-8 °C: See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer: 12 weeks

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum.

Plasma: Li-heparin plasma

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Stability: ⁵	4 days at 20-25 °C
	8 days at 4-8 °C
	8 days at -20 °C

The degree of fragmentation of C3 to C3c depends on the age and storage conditions of the sample. For fresh samples the values obtained are found to be up to 25 % lower than those obtained for aged samples depending on the extent to which fragmentation has occurred.⁶

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- See "Order information" section
- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum and plasma**cobas c 311 test definition**

Assay type	2-Point End		
Reaction time / Assay points	10 / 6-24		
Wavelength (sub/main)	700/340 nm		
Reaction direction	Increase		
Units	g/L (mg/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	90 µL	–	
R2	17 µL	20 µL	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	10 µL	9 µL	180 µL
Decreased	10 µL	4 µL	164 µL
Increased	10 µL	9 µL	180 µL

cobas c 501 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 10-46		
Wavelength (sub/main)	700/340 nm		
Reaction direction	Increase		
Units	g/L (mg/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	90 µL	–	
R2	17 µL	20 µL	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	10 µL	9 µL	180 µL
Decreased	10 µL	4 µL	164 µL
Increased	10 µL	9 µL	180 µL

cobas c 502 test definition

Assay type	2-Point End		
Reaction time / Assay points	10 / 10-46		
Wavelength (sub/main)	700/340 nm		

Reaction direction	Increase		
Units	g/L (mg/dL)		
Reagent pipetting	Diluent (H ₂ O)		
R1	90 µL	–	
R2	17 µL	20 µL	
<i>Sample volumes</i>	<i>Sample</i>	<i>Sample dilution</i>	
		<i>Sample</i>	<i>Diluent (NaCl)</i>
Normal	10 µL	9 µL	180 µL
Decreased	10 µL	4 µL	164 µL
Increased	10 µL	18 µL	180 µL

Calibration

Calibrators	S1: H ₂ O		
	S2: C.f.a.s. Proteins		
	Multiply the lot-specific C.f.a.s. Proteins calibrator value by the factors below to determine the standard concentrations for the 6-point calibration curve:		
	S2: 0.105	S5: 1.05	
	S3: 0.210	S6: 2.10	
	S4: 0.420		
Calibration mode	RCM2		
Calibration frequency	Full calibration		
	<ul style="list-style-type: none"> • after reagent lot change • as required following quality control procedures 		

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the reference preparation of the IRMM (Institute for Reference Materials and Measurements) BCR470/CRM470 (RPPHS - Reference Preparation for Proteins in Human Serum).⁷

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

Roche/Hitachi **cobas c** systems automatically calculate the analyte concentration of each sample.

Conversion factors:	g/L x 100 = mg/dL
	mg/dL x 0.01 = g/L

Limitations - interference

Criterion: Recovery within ± 10 % of initial values at C3c levels of 0.9 g/L.

Icterus:⁸ No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 µmol/L or 60 mg/dL).

Hemolysis:⁸ No significant interference up to an H index of 1000 (approximate hemoglobin concentration: 621 µmol/L or 1000 mg/dL).

Lipemia (Intralipid):⁸ No significant interference up to an L index of 2000. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Rheumatoid factors up to 1200 IU/mL do not interfere.

High dose hook-effect: No false result occurs up to a C3c concentration of 12.5 g/L.

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{9,10}

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹¹

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c** 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

0.04-5.0 g/L (4-500 mg/dL)

Determine samples having higher concentrations via the rerun function. Dilution of samples via the rerun function is a 1:2 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 2.

Lower limits of measurement

Lower detection limit of the test

0.04 g/L (4 mg/dL)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from zero. It is calculated as the value lying 3 standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

Expected values¹²

0.9-1.8 g/L (90-180 mg/dL)

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 21 days). The following results were obtained:

<i>Repeatability</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>g/L (mg/dL)</i>	<i>g/L (mg/dL)</i>	<i>%</i>
Precinorm Protein	1.17 (117)	0.01 (1)	0.9
Precipath Protein	2.05 (205)	0.02 (2)	0.9
Human serum 1	1.40 (140)	0.01 (1)	0.8
Human serum 2	1.85 (185)	0.02 (2)	1.2
<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>g/L (mg/dL)</i>	<i>g/L (mg/dL)</i>	<i>%</i>
Precinorm Protein	1.14 (114)	0.02 (2)	1.4
Precipath Protein	2.02 (202)	0.04 (4)	1.8
Human serum 3	1.43 (143)	0.02 (2)	1.3
Human serum 4	2.09 (209)	0.04 (4)	2.0

The data obtained on **cobas c** 501 analyzer(s) are representative for **cobas c** 311 analyzer(s).

Method comparison

C3c values for human serum and plasma samples obtained on a Roche/Hitachi **cobas c** 501 analyzer (y) were compared with those determined using the corresponding reagent on a Roche/Hitachi 917 analyzer (x).

Sample size (n) = 266

Passing/Bablok¹³

$y = 0.981x + 0.034$ g/L

$\tau = 0.913$

Linear regression

$y = 0.963x + 0.056$ g/L

$r = 0.989$

The sample concentrations were between 0.530 and 3.00 g/L (53.0 and 300 mg/dL).

The data obtained on **cobas c** 501 analyzer(s) are representative for **cobas c** 311 analyzer(s).

References

- Greiling H, Gressner AM, eds. Lehrbuch der Klinischen Chemie und Pathobiochemie, 3rd ed. Stuttgart/New York: Schattauer Verlag 1995;1159-1162.
- Müller-Eberhard HJ. Complement: Chemistry and pathways. In: Inflammation: Basic principles and clinical correlates. Gallin I, Goldstein IM, Snyderman R, eds. New York: Raven Press 1988;21-53.
- Thomas L, ed. Labor und Diagnose, 5th ed. Frankfurt: TH-Books Verlagsgesellschaft mbH 1998;812-823.
- Tietz NW, ed. Clinical Guide to Laboratory Tests, 3rd ed. Philadelphia, PA: WB Saunders Company 1995;164-165.
- Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev. 2: Jan 2002.
- Okumura N, Nomura M, Tada T, et al. Effects of sample storage on serum C3C assay by nephelometry. Clin Lab Sci 1990;3:54-57.
- Baudner S, Bienvenu J, Blirup-Jensen S, et al. The certification of a matrix reference material for immunochemical measurement of 14 human serum proteins CRM470. Report EUR 15243 EN 1993;1-186.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem 1996;34:517-520.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see dialog.roche.com for definition of symbols used):

CONTENT

Contents of kit

0003001938322c501V10.0

C3C-2

Tina-quant Complement C3c ver.2

cobas®



Volume after reconstitution or mixing

GTIN

Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C, PRECICONTROL, PRECINORM, PRECIPATH and TINA-QUANT are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2020, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com

+800 5505 6606



Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336